AI takes on liver cancer: smart dosing trial launches

NCT ID NCT05669339

Recruiting now Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This phase 2 trial is testing whether an artificial intelligence system can find the best doses of three drugs (irinotecan, sonidegib, and sorafenib) for people with advanced liver cancer. The study will enroll 12 adults whose cancer has not responded to other treatments. The goal is to find safe dose levels and see if this personalized approach can shrink tumors with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: combination of irinotecan, sonidegib, and sorafenib
What this could lead to: If successful, this could lead to a safer, more effective way to dose multiple drugs for advanced liver cancer, potentially improving survival and quality of life.
What could go wrong: This is a very small early-phase trial (12 people) focused on finding safe doses, not proving the treatment works. The drug combination may still cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

University of Florida
RECRUITING

Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.